Comprehensive Financial Consultants Institutional Inc. Boosts Holdings in DexCom, Inc. (NASDAQ:DXCM)

Comprehensive Financial Consultants Institutional Inc. lifted its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 41.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 10,383 shares of the medical device company's stock after purchasing an additional 3,049 shares during the period. Comprehensive Financial Consultants Institutional Inc.'s holdings in DexCom were worth $807,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the business. Versant Capital Management Inc bought a new position in DexCom in the 4th quarter worth approximately $25,000. Riverview Trust Co increased its position in DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock worth $31,000 after acquiring an additional 232 shares during the period. Heck Capital Advisors LLC acquired a new position in DexCom during the 4th quarter valued at $38,000. MassMutual Private Wealth & Trust FSB boosted its holdings in DexCom by 46.7% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company's stock valued at $65,000 after purchasing an additional 265 shares during the period. Finally, RPg Family Wealth Advisory LLC acquired a new stake in DexCom in the 3rd quarter worth $57,000. Institutional investors and hedge funds own 97.75% of the company's stock.

Insider Buying and Selling

In other news, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the sale, the executive vice president now owns 83,526 shares in the company, valued at $7,259,244.66. This represents a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Sadie Stern sold 4,259 shares of the business's stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now owns 71,192 shares in the company, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 42,342 shares of company stock valued at $3,628,069 over the last ninety days. 0.30% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

DXCM has been the topic of a number of recent research reports. Sanford C. Bernstein lifted their target price on DexCom from $82.00 to $86.00 and gave the stock an "outperform" rating in a research report on Friday, October 25th. Canaccord Genuity Group lifted their price objective on DexCom from $89.00 to $99.00 and gave the stock a "buy" rating in a report on Monday, December 9th. Raymond James cut their target price on DexCom from $115.00 to $99.00 and set a "strong-buy" rating for the company in a research note on Friday, October 25th. Wells Fargo & Company raised their price objective on shares of DexCom from $90.00 to $94.00 and gave the stock an "overweight" rating in a report on Wednesday, December 11th. Finally, Robert W. Baird upgraded DexCom from a "neutral" rating to an "outperform" rating and increased their price objective for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Four investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $98.41.

DexCom Trading Up 0.8 %

NASDAQ:DXCM traded up $0.73 on Wednesday, reaching $88.19. 752,118 shares of the stock traded hands, compared to its average volume of 3,334,315. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The company's 50 day moving average is $81.14 and its 200-day moving average is $75.60. The firm has a market capitalization of $34.45 billion, a price-to-earnings ratio of 52.85, a price-to-earnings-growth ratio of 2.23 and a beta of 1.14.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.